Clinical Trials Logo

Filter by:
NCT ID: NCT00407108 Withdrawn - Clinical trials for Diabetic Retinopathy

Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy

Start date: March 2006
Phase: Phase 3
Study type: Interventional

To investigate the feasibility and advantages of using perfluorocarbon liquid (PCL) perfusion to remove vitreous during suction-cutting vitrectomy using a dual, dynamic drive (3D)technology. In complicated surgeries in advanced diabetic retinopathy and retinal detachment

NCT ID: NCT00406848 Completed - Clinical trials for Major Depressive Disorder

A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients

Start date: November 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of duloxetine 60 mg once daily to placebo on depression in elderly patients (greater than or equal to 65 years of age). Patients who do not respond in the first 13 weeks will be eligible for rescue using pre-defined criteria. Patients randomized to duloxetine 60 mg/day meeting the rescue criteria will be increased to 120 mg/day. Patients randomized to the placebo arm meeting the rescue criteria will be assigned to duloxetine 60 mg/day.

NCT ID: NCT00406744 Terminated - Clinical trials for Age Related Macular Degeneration

Efficacy of Retreatments With Intravitreal Bevacizumab

Start date: May 2006
Phase: Phase 3
Study type: Interventional

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

NCT ID: NCT00406653 Terminated - Crohn's Disease Clinical Trials

A Study of Abatacept in Patients With Active Crohn's Disease

Start date: December 2006
Phase: Phase 3
Study type: Interventional

The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn's Disease in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied.

NCT ID: NCT00406640 Completed - Depression Clinical Trials

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

Start date: December 2006
Phase: Phase 3
Study type: Interventional

Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability of DVS SR versus escitalopram in women with major depressive disorder (MDD) who are postmenopausal.

NCT ID: NCT00406458 Completed - Clinical trials for Diabetes Mellitus, Type 2

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Start date: November 2006
Phase: Phase 2
Study type: Interventional

The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.

NCT ID: NCT00406380 Withdrawn - Telangiectasis Clinical Trials

Effect of Avastin in Juxtafoveal Telangiectasias

Start date: September 2006
Phase: Phase 3
Study type: Interventional

Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal Telangiectasias

NCT ID: NCT00406172 Withdrawn - Clinical trials for Cystoid Macular Edema

Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)

Start date: November 2006
Phase: Phase 3
Study type: Interventional

To report safety and efficacy of intravitreal injection of bevacizumab in patients with cystoid macular edema secondary to cataract surgery.

NCT ID: NCT00405808 Terminated - Obesity Clinical Trials

Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose

PRADO
Start date: December 2006
Phase: Phase 3
Study type: Interventional

Primary objective: To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with impaired fasting blood glucose and with or without associated comorbidities. Main Secondary objectives: To determine the effect of 12 months Rimonabant treatment versus placebo on changes in waist circumference (WC), body weight, glycemic parameters and lipid parameters. To assess the safety of 12 months Rimonabant treatment versus placebo in these patients.

NCT ID: NCT00404924 Completed - Clinical trials for Non-Small-Cell Lung Carcinoma

ZD6474 (ZACTIMAâ„¢) Phase III Study in EGFR Failures

Start date: November 2006
Phase: Phase 3
Study type: Interventional

This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred after previous chemotherapy and an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). ZD6474 is a new anti-cancer drug in development that works in a different way to standard chemotherapy drugs. It targets the growth of new blood vessels to a tumour and thereby might slow the rate at which the tumour may grow. Early studies indicate that ZD6474 has a positive effect on the time that a tumour may take to progress to a further stage. Approximately 930 patients will take part in this study. It will be conducted in hospitals and clinics in North and South America, Europe and Asia.